Stox
30
Syngene International Ltd.
NSE: SYNGENE · Healthcare
₹417.30+0.77%06 Nov 2026
Ask the data
Instant answers about Syngene International Ltd. — computed from its filings, no language modelMarket cap₹16,846 cr
Current price₹417.30
High / Low₹664 / ₹346
P/E441.0
P/B3.47
Book value₹120.4
ROE0.8%
ROCE6.0%
Debt / equity0.01
Dividend yield0.30%
EPS (TTM)₹0.95
Face value₹10
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 | 3,739 |
| EBITDA | 537 | 618 | 672 | 796 | 934 | 1,014 | 1,042 | 918 |
| Operating margin | 29.4% | 30.7% | 30.8% | 30.6% | 29.3% | 29.1% | 28.6% | 24.6% |
| Interest | 32 | 35 | 28 | 24 | 45 | 47 | 53 | 49 |
| Depreciation | 164 | 219 | 274 | 310 | 366 | 426 | 433 | 453 |
| Profit before tax | 415 | 517 | 469 | 484 | 594 | 621 | 660 | 411 |
| Tax | 84 | 105 | 64 | 89 | 129 | 111 | 164 | 94 |
| Net profit | 332 | 0 | 405 | 0 | 0 | 510 | 0 | 0 |
| EPS ₹ | 16.77 | 10.38 | 10.18 | 9.94 | 11.59 | 12.71 | 12.35 | 7.87 |
| Operating cash flow | — | — | — | 581 | 824 | 1,042 | 1,168 | 915 |
| Capex | — | — | — | 476 | 518 | 511 | 770 | 368 |
| Dividend paid | — | — | — | 0 | 40 | 50 | 50 | 50 |
| Total assets | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 7,055 |
| Equity | 1,968 | 2,176 | 2,821 | 3,298 | 3,618 | 4,258 | 4,727 | 4,839 |
Quarterly performance
last 32 quarters · ₹ crore| JUN '18 | DEC '18 | MAR '19 | JUN '19 | SEP '19 | DEC '19 | MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 406 | 467 | 534 | 421 | 465 | 519 | 607 | 422 | 520 | 584 | 659 | 594 | 610 | 641 | 758 | 768 | 786 | 994 | 808 | 910 | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 | 911 | 917 | 1,036 | 736 | 833 |
| Operating profit | 110 | 141 | 160 | 121 | 139 | 154 | 204 | 124 | 156 | 176 | 215 | 165 | 177 | 203 | 250 | 216 | 231 | 314 | 212 | 254 | 232 | 317 | 170 | 245 | 284 | 344 | 206 | 200 | 209 | 303 | 91 | 147 |
| Operating margin | 27.0% | 30.1% | 30.0% | 28.8% | 30.0% | 29.6% | 33.6% | 29.5% | 30.0% | 30.1% | 32.7% | 27.8% | 29.1% | 31.7% | 33.0% | 28.2% | 29.4% | 31.6% | 26.2% | 27.9% | 27.1% | 34.6% | 21.5% | 27.5% | 30.1% | 33.8% | 23.6% | 21.9% | 22.8% | 29.3% | 12.3% | 17.7% |
| Other income | 19 | 17 | 21 | 20 | 21 | 20 | 20 | 15 | 14 | 17 | 18 | 12 | 13 | 13 | 15 | 15 | 17 | 23 | 24 | 22 | 29 | 16 | 18 | 16 | 18 | 19 | 18 | 15 | 15 | 22 | 25 | 28 |
| Interest | 8 | 8 | 8 | 7 | 8 | 10 | 9 | 7 | 7 | 7 | 7 | 8 | 1 | 9 | 6 | 12 | 14 | 10 | 10 | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 | 13 | 12 | 12 | 10 | 10 |
| Depreciation | 37 | 43 | 44 | 47 | 53 | 57 | 62 | 66 | 69 | 70 | 70 | 75 | 76 | 78 | 80 | 90 | 95 | 96 | 102 | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 | 116 | 114 | 112 | 112 | 112 |
| Profit before tax | 83 | 107 | 129 | 87 | 170 | 107 | 153 | 66 | 94 | 116 | 192 | 95 | 82 | 128 | 179 | 130 | 140 | 231 | 123 | 151 | 138 | 209 | 101 | 137 | 181 | 240 | 101 | 85 | 28 | 196 | -19 | 47 |
| Tax | 17 | 20 | 29 | 15 | 42 | 15 | 33 | 8 | 10 | 14 | 32 | 17 | 16 | 24 | 31 | 28 | 30 | 52 | 30 | 34 | 27 | 20 | 26 | 31 | 50 | 57 | 15 | 18 | 13 | 48 | -10 | 15 |
| Net profit | 66 | 0 | 100 | 0 | 128 | 0 | 0 | 0 | 84 | 102 | 161 | 77 | 0 | 104 | 0 | 102 | 0 | 0 | 93 | 116 | 112 | 189 | 76 | 106 | 0 | 0 | 0 | 0 | 15 | 0 | -9 | 32 |
| EPS ₹ | 3.34 | 4.39 | 5.05 | 1.82 | 3.23 | 2.32 | 3.03 | 1.47 | 2.12 | 2.57 | 4.04 | 1.91 | 1.64 | 2.57 | 3.71 | 2.55 | 2.74 | 4.46 | 2.33 | 2.90 | 2.78 | 4.70 | 1.89 | 2.64 | 3.27 | 4.56 | 2.16 | 1.67 | 0.37 | 3.68 | -0.22 | 0.80 |
| Revenue YoY | — | — | — | 3.7% | — | 11.1% | 13.7% | 0.2% | 11.8% | 12.6% | 8.4% | 41.0% | 17.4% | 9.7% | 15.1% | 25.9% | 22.5% | 31.2% | — | 18.5% | 8.6% | -7.8% | -2.3% | -2.1% | 10.6% | 11.0% | 10.7% | 2.2% | -2.8% | 1.8% | -15.8% | -8.6% |
| Profit YoY | — | — | — | -100.0% | — | — | -100.0% | — | -34.3% | — | — | — | -100.0% | 1.8% | -100.0% | — | -100.0% | — | — | 14.2% | — | — | -19.0% | -8.9% | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — |
Earlier results (standalone, Sep '15 – Mar '18)
₹ crore · from BSE, before the NSE XBRL filings beginSyngene International Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.
Full years
| FY17† | FY18† | |
|---|---|---|
| Revenue | 1,201 | 1,423 |
| Operating profit | 408 | 464 |
| Operating margin | 33.9% | 32.6% |
| Other income | 71 | 62 |
| Interest | 18 | 23 |
| Depreciation | 114 | 131 |
| Profit before tax | 346 | 372 |
| Tax | 59 | 67 |
| Net profit | 287 | 305 |
Quarters
| SEP '15† | DEC '15† | MAR '16† | JUN '16† | SEP '16† | DEC '16† | MAR '17† | JUN '17† | SEP '17† | DEC '17† | MAR '18† | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 261 | 280 | 332 | 274 | 303 | 332 | 291 | 291 | 335 | 388 | 409 |
| Operating profit | 86 | 94 | 103 | 89 | 106 | 113 | 100 | 96 | 114 | 126 | 129 |
| Operating margin | 32.8% | 33.5% | 31.1% | 32.3% | 34.9% | 34.0% | 34.5% | 33.0% | 33.9% | 32.5% | 31.5% |
| Other income | 1 | 0 | 3 | 16 | 16 | 15 | 24 | 17 | 16 | 12 | 17 |
| Interest | 2 | 1 | 1 | 5 | 3 | 7 | 3 | 5 | 5 | 5 | 7 |
| Depreciation | 24 | 25 | 26 | 27 | 28 | 29 | 31 | 32 | 30 | 35 | 34 |
| Profit before tax | 61 | 68 | 79 | 73 | 91 | 92 | 90 | 76 | 94 | 98 | 104 |
| Tax | 8 | 9 | 12 | 13 | 17 | 17 | 12 | 14 | 18 | 16 | 20 |
| Net profit | 52 | 59 | 66 | 60 | 75 | 74 | 78 | 62 | 77 | 82 | 84 |
| EPS ₹ | 2.61 | 3.03 | 3.43 | 3.08 | 3.81 | 3.80 | 4.00 | 3.16 | 3.88 | 4.14 | 4.26 |
| Revenue YoY | — | — | — | — | 15.9% | 18.4% | -12.1% | 6.0% | 10.6% | 16.7% | 40.4% |
| Profit YoY | — | — | — | — | 42.9% | 26.5% | 17.9% | 3.7% | 2.9% | 10.1% | 7.5% |
Returns & margins
trailing-twelve-month, per quarter| SEP '19 | DEC '19 | MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.6% | 11.6% | 5.9% | 5.9% | 3.9% | 8.6% | 12.3% | 15.0% | 12.1% | 12.1% | 5.5% | 5.4% | 5.4% | 8.3% | 12.0% | 11.6% | 11.0% | 8.4% | 3.8% | 2.2% | 0.0% | 0.3% | 0.3% | 0.1% | 0.8% |
| ROCE | 20.9% | 21.0% | 22.2% | 21.4% | 18.2% | 18.5% | 13.8% | 14.6% | 14.1% | 14.5% | 12.4% | 16.0% | 15.7% | 15.6% | 15.2% | 14.7% | 13.9% | 14.9% | 14.7% | 14.7% | 13.6% | 10.5% | 9.5% | 7.0% | 6.0% |
| Net margin | 12.1% | 11.8% | 6.4% | 6.4% | 4.1% | 8.7% | 15.9% | 18.0% | 13.9% | 13.7% | 7.0% | 5.8% | 6.0% | 9.0% | 14.6% | 14.2% | 14.0% | 10.5% | 5.0% | 2.8% | 0.0% | 0.4% | 0.4% | 0.2% | 1.1% |
| EBITDA margin | 29.7% | 29.6% | 30.7% | 30.9% | 30.8% | 31.0% | 30.8% | 30.2% | 30.0% | 30.4% | 30.6% | 29.0% | 28.9% | 28.4% | 29.1% | 28.0% | 27.9% | 28.7% | 28.6% | 28.9% | 27.6% | 25.8% | 24.6% | 22.3% | 21.3% |
| Debt / equity | 0.27 | 0.27 | 0.14 | 0.14 | 0.14 | 0.14 | 0.27 | 0.27 | 0.27 | 0.27 | 0.24 | 0.16 | 0.13 | 0.13 | 0.03 | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.01 |
| Interest coverage | 16.54 | 15.79 | 15.94 | 15.21 | 13.69 | 15.14 | 17.94 | 18.65 | 22.30 | 20.82 | 21.10 | 14.47 | 14.54 | 15.38 | 14.15 | 13.38 | 13.08 | 13.54 | 13.43 | 13.45 | 12.45 | 9.66 | 9.42 | 7.21 | 6.78 |
| Asset turnover | 0.51 | 0.52 | 0.48 | 0.48 | 0.50 | 0.51 | 0.45 | 0.48 | 0.50 | 0.51 | 0.47 | 0.58 | 0.60 | 0.61 | 0.57 | 0.56 | 0.56 | 0.58 | 0.54 | 0.55 | 0.57 | 0.57 | 0.53 | 0.51 | 0.53 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '18‡ | MAR '19‡ | MAR '20‡ | MAR '21‡ | MAR '22‡ | SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | MAR '25 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share capital | 200 | 200 | 400 | 400 | 401 | 401 | 401 | 402 | 402 | 402 | 402 | 403 | 403 | 404 |
| Other equity / reserves | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 2,872 | 3,217 | 3,489 | 3,856 | 3,993 | 4,324 | 4,332 | 4,436 | 4,455 |
| Total equity | 1,720 | 1,968 | 2,176 | 2,821 | 3,298 | 3,274 | 3,618 | 3,891 | 4,258 | 4,396 | 4,727 | 4,735 | 4,839 | 4,859 |
| Borrowings | 664 | 537 | 309 | 772 | 790 | 770 | 575 | 520 | 142 | 159 | 120 | 124 | 9 | 67 |
| Current liabilities | 784 | 1,129 | 1,539 | 1,133 | 1,229 | 1,035 | 1,188 | 1,226 | 1,144 | 941 | 1,396 | 1,192 | 1,552 | 1,183 |
| Non-current liabilities | 685 | 606 | 448 | 929 | 1,037 | 1,072 | 1,025 | 729 | 750 | 800 | 673 | 615 | 663 | 617 |
| Total assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,381 | 5,831 | 5,846 | 6,152 | 6,136 | 6,796 | 6,542 | 7,055 | 6,658 |
| Property, plant & equipment | 1,012 | 1,323 | 1,877 | 2,032 | 2,123 | 2,262 | 2,383 | 2,682 | 2,378 | 2,794 | 2,323 | 2,572 | 2,545 | 2,448 |
| Capital work-in-progress | 155 | 274 | 234 | 237 | 346 | 229 | 177 | 236 | 837 | 904 | 1,261 | 989 | 1,040 | 1,141 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 960 | 918 | 540 | 548 | 539 | 647 | 547 | 741 | 610 |
| Inventories | 86 | 43 | 25 | 60 | 179 | 267 | 333 | 320 | 238 | 170 | 156 | 189 | 141 | 168 |
| Receivables | 267 | 339 | 398 | 476 | 508 | 440 | 529 | 419 | 442 | 484 | 527 | 532 | 509 | 386 |
| Cash & equivalents | 253 | 165 | 193 | 323 | 262 | 159 | 90 | 168 | 86 | 221 | 367 | 327 | 229 | 120 |
Cash flow
annual · ₹ crore · line = free cash flow| FY18‡ | FY19‡ | FY20‡ | FY21‡ | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 446 | 630 | 677 | 701 | 581 | 824 | 1,042 | 1,168 | 915 |
| Cash from investing | -349 | -646 | -428 | -628 | -612 | -656 | -496 | -745 | -860 |
| Cash from financing | -79 | -72 | -226 | 58 | -31 | -342 | -551 | -142 | -215 |
| Capex | 364 | 583 | 643 | 446 | 476 | 518 | 511 | 770 | 368 |
| Free cash flow | 82 | 47 | 34 | 255 | 105 | 305 | 531 | 398 | 547 |
| Dividends paid | 24 | 24 | 24 | — | 0 | 40 | 50 | 50 | 50 |
Where the assets sit
Sep '26 · ₹ croreFixed assets (PPE)₹2,448 cr37%
CWIP₹1,141 cr17%
Investments₹610 cr9%
Inventories₹168 cr3%
Receivables₹386 cr6%
Cash & equivalents₹120 cr2%
Other assets₹1,787 cr27%
Peer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Syngene International Ltd. | 16,846 | 417.30 | 441.0 | 3.47 | 0.8% |
StoxGud checklist: Bearish setup · 3/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month+15.8%
6 months-10.7%
1 year-36.7%
3Y CAGR-16.4%
5Y CAGR-5.3%
10Y CAGR+4.3%
50-day avg₹384.89
200-day avg₹425.12
RSI (14)60
Compare Syngene International Ltd. with
FAQs
What is the share price of Syngene International Ltd.?
Syngene International Ltd. (SYNGENE) closed at ₹417.30 on NSE on 06 Nov 2026.
What is the market cap of Syngene International Ltd.?
₹16,846 crore at the latest close.
What is the P/E ratio of Syngene International Ltd.?
441.0, on trailing-twelve-month earnings from its filings.
How fast is Syngene International Ltd. growing?
Syngene International Ltd.: revenue has compounded at 5.4% a year over three years. Latest-quarter revenue is down 8.6% year on year.
How profitable is Syngene International Ltd.?
On a trailing-twelve-month basis return on equity is 0.8%, return on capital employed 6.0%, operating margin 21.3%, net margin 1.1%.
How much debt does Syngene International Ltd. have?
Syngene International Ltd. is debt-free: debt to equity is 0.01 with borrowings of ₹67 cr against cash of ₹120 cr (balance sheet of 2026-09-30). Operating profit covers interest 6.8 times.
Financials parsed from Syngene International Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '18, annual from FY19, balance sheet from Mar '18. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.
Syngene International Ltd. · advanced chart